Retatrutide vs Survodutide: Comparing Two Glucagon-Containing Agonists

Overview

Retatrutide and survodutide represent two approaches to incorporating glucagon receptor agonism into incretin-based therapy, but from opposite directions. Retatrutide adds GCGR to the GIP/GLP-1 dual agonist framework (creating a triple agonist). Survodutide (developed by Boehringer Ingelheim, also known as BI 456906) adds GCGR to GLP-1R agonism (creating a GLP-1/glucagon dual agonist, without GIP). This comparison illuminates the role of GIP receptor agonism as the differentiating variable.

With Phase 3 TRIUMPH-4 data now available for retatrutide (-28.7% weight loss at 68 weeks), and survodutide’s Phase 3 program advancing in parallel, this comparison has become increasingly relevant for understanding how different glucagon-containing multi-agonist designs perform in clinical settings.

Important caveat: No head-to-head trial exists between these compounds. Cross-trial comparisons have significant limitations.

Why This Comparison Matters

The retatrutide versus survodutide comparison is uniquely valuable in metabolic pharmacology:

• These are the only two advanced-stage drugs that include glucagon receptor agonism, allowing us to study its effects in different receptor combinations
• The comparison isolates the value of GIP receptor agonism: retatrutide has it, survodutide does not, while both share GLP-1 and glucagon receptor activity
• Both drugs are positioned for the MASLD/MASH indication, where glucagon receptor activation provides direct hepatic benefit — making this comparison particularly relevant for liver disease treatment
• The two drugs come from different companies (Eli Lilly and Boehringer Ingelheim) with different development strategies, providing insight into how the same pharmacological principle (glucagon receptor engagement) can be deployed in different clinical contexts
• With retatrutide TRIUMPH-4 Phase 3 data now available, and survodutide Phase 3 results pending, this comparison will become increasingly data-driven in the coming months

Mechanism Comparison

Shared Pathways

Both molecules share two receptor targets:

• GLP-1 receptor: Providing appetite suppression, glycemic control, and gastric motility effects
• Glucagon receptor: Providing increased energy expenditure and hepatic fatty acid oxidation

This shared GCGR component means both drugs are expected to produce the increased energy expenditure and liver fat reduction that characterize glucagon-containing agonists. The hepatic effects of glucagon receptor activation — stimulating mitochondrial fatty acid oxidation, enhancing thermogenesis, and promoting lipid clearance — are mechanistically identical in both molecules.

The Differentiating Factor: GIP Receptor

The key difference is the presence (retatrutide) or absence (survodutide) of GIP receptor agonism:

The presence of GIPR agonism in retatrutide may provide additional benefits in adipose tissue function, insulin secretion, and potentially body composition during weight loss. Conversely, survodutide’s simpler two-receptor design may offer manufacturing advantages and a potentially more predictable pharmacological profile.

TRIUMPH-4 Phase 3 Results

The release of TRIUMPH-4 data in December 2025 provided the first Phase 3-level evidence for retatrutide’s efficacy. In 768 adults with obesity and knee osteoarthritis:

• Retatrutide 12 mg: -28.7% mean weight loss at 68 weeks
• Retatrutide 8 mg: -25.4% mean weight loss at 48 weeks
• 99% of participants at 12 mg achieved at least 5% weight loss
• 75% reduction in knee osteoarthritis pain scores

These results represent the largest weight loss ever achieved by any pharmaceutical agent in a Phase 3 trial, substantially exceeding Phase 2 data (-24.2% at 48 weeks) and widening the apparent gap between retatrutide and survodutide’s Phase 2 weight loss results.

TRIUMPH-4 also identified a new safety signal: dysesthesia (abnormal sensory sensations) in 20.9% of participants at 12 mg versus 0.7% on placebo.

Efficacy Comparison

Weight Loss

Cross-trial observations (with significant caveats):

Retatrutide produces numerically greater weight loss at both Phase 2 and Phase 3 levels, potentially reflecting the additional GIPR contribution to appetite suppression and the overall synergy of triple versus dual agonism. The gap widened from approximately 5-6 percentage points in Phase 2 cross-trial comparisons to approximately 10 percentage points when comparing TRIUMPH-4 Phase 3 data to survodutide’s Phase 2 results.

However, survodutide’s Phase 3 obesity data have not yet been reported as of March 2026. The Phase 3 dose, trial duration, and population may produce different results than Phase 2.

Liver Fat

Both molecules demonstrate substantial liver fat reduction, driven by their shared glucagon receptor component:

• Survodutide: Demonstrated significant liver fat reduction in Phase 2, with particular focus on the MASLD/MASH population. Boehringer Ingelheim has prioritized MASH as a key indication, with liver biopsy endpoint trials. Phase 2 data showed clinically meaningful histological improvement in MASH patients.
• Retatrutide: Demonstrated ~82% relative liver fat reduction in Phase 2. The hepatic effect may be further enhanced by GIPR-mediated improvements in insulin sensitivity and peripheral fat handling. Eli Lilly’s SYNERGY trial is evaluating retatrutide for MASH.

Both compounds are positioned as potential MASLD/MASH therapeutics, and their liver fat effects may be among the most potent observed for any pharmacological class.

Glycemic Control

Retatrutide may have a glycemic advantage due to the additional insulinotropic effect of GIPR agonism. The combined GLP-1R + GIPR insulin stimulation in retatrutide provides more robust glucose-dependent insulin secretion, which more effectively offsets the glucose-raising effect of GCGR agonism. Survodutide relies solely on GLP-1R-mediated insulin secretion to counterbalance GCGR-driven hepatic glucose output, which may result in a narrower therapeutic window for glycemic safety.

In Phase 2 type 2 diabetes data, retatrutide achieved HbA1c reductions of approximately -2.02%, while survodutide’s glycemic data have been more limited in published literature.

Safety Considerations

Gastrointestinal Events

Both compounds produce GLP-1R-mediated GI adverse events. The addition of GIPR agonism in retatrutide does not appear to substantially worsen the GI profile based on available data. Survodutide’s Phase 2 data also showed a GI profile consistent with GLP-1R agonism, with nausea, vomiting, and diarrhea as the most common adverse events.

Dysesthesia

TRIUMPH-4 identified dysesthesia as a new safety signal for retatrutide (20.9% at 12 mg versus 0.7% placebo). It remains unclear whether this effect is related to the glucagon receptor component (which would theoretically affect survodutide as well) or to the specific triple receptor combination. Survodutide’s Phase 2 data did not report a comparable dysesthesia signal, but smaller Phase 2 sample sizes may have limited detection.

Glycemic Safety

The balance between GCGR-mediated glucose raising and GLP-1R-mediated glucose lowering is a critical safety consideration for both drugs. Retatrutide’s additional GIPR insulinotropism may provide a wider glycemic safety margin, reducing the risk that GCGR activity could cause hyperglycemia. Survodutide must rely entirely on GLP-1R activity to counterbalance GCGR effects.

Hepatic Safety

Both molecules require long-term monitoring of hepatic function given chronic GCGR activation. The shared glucagon receptor component means both compounds theoretically carry similar hepatic safety considerations, though the specific receptor potency ratios and tissue exposure profiles may differ.

Development Strategy Differences

Boehringer Ingelheim (Survodutide)

Boehringer Ingelheim has positioned survodutide with a strong emphasis on MASLD/MASH, launching dedicated liver disease trials with histological endpoints (liver biopsy before and after treatment). This MASH-focused development strategy reflects both the compound’s mechanism (GLP-1/glucagon dual agonism is well-suited to liver disease) and a strategic decision to differentiate from the crowded obesity/diabetes competitive landscape. Phase 3 trials for both obesity and MASH are underway as of March 2026.

Eli Lilly (Retatrutide)

Eli Lilly’s Phase 3 TRIUMPH program primarily targets obesity and type 2 diabetes indications, with 7 TRIUMPH trials plus the TRANSCEND (type 2 diabetes) and SYNERGY (MASH) studies. TRIUMPH-4, the first to report, focused on obesity with knee osteoarthritis. Liver fat reduction is an important secondary outcome, and the dedicated SYNERGY MASH trial demonstrates Eli Lilly’s interest in the hepatic indication as well.

Current Status and Availability

Retatrutide

Retatrutide is in Phase 3 development. TRIUMPH-4 results were published in December 2025, with additional Phase 3 readouts expected in late 2026-2027. No NDA has been filed. Earliest possible FDA approval is estimated at late 2027-2028. Available only through clinical trial enrollment.

Survodutide

Survodutide is in Phase 3 development for both obesity and MASH indications. Phase 3 results have not yet been reported as of March 2026. Boehringer Ingelheim has not disclosed specific anticipated approval timelines. Available only through clinical trial enrollment.

What This Comparison Reveals About GIP

The retatrutide-versus-survodutide comparison provides indirect evidence about the value of GIP receptor agonism when added to a GLP-1/glucagon framework:

1. Enhanced weight loss: The numerically greater weight loss with retatrutide (triple) versus survodutide (GLP-1/glucagon dual) suggests that GIPR agonism provides additional weight benefit, now supported by Phase 3 TRIUMPH-4 data
2. Glycemic safety margin: GIPR insulinotropism likely widens the therapeutic window for safely incorporating GCGR agonism
3. Adipose tissue effects: GIPR-mediated effects on fat tissue may contribute to body composition optimization during weight loss
4. Incremental complexity: Each additional receptor target adds pharmacological complexity, potentially complicating dose optimization and safety characterization — as illustrated by the dysesthesia signal in TRIUMPH-4

Key Differences Summary

The MASH Treatment Landscape

Both retatrutide and survodutide are positioned to potentially address metabolic dysfunction-associated steatohepatitis (MASH), a condition affecting an estimated 6-8 million Americans with limited approved treatment options.

Why Glucagon-Containing Agonists Are Promising for MASH

The glucagon receptor directly stimulates hepatic fatty acid oxidation, a mechanism uniquely suited to reducing liver fat. Unlike GLP-1-only agonists that reduce liver fat primarily through weight loss and improved insulin sensitivity, glucagon receptor activation drives a direct hepatic effect:

• Increased mitochondrial beta-oxidation of fatty acids in hepatocytes
• Enhanced hepatic energy expenditure
• Reduced de novo lipogenesis when combined with GLP-1R-mediated insulin sensitization

Both retatrutide and survodutide produce liver fat reductions that appear to exceed those achieved by GLP-1-only or GIP/GLP-1 dual agonists, confirming the hepatic benefit of glucagon receptor engagement.

Competitive Positioning

Boehringer Ingelheim’s concentrated focus on MASH may give survodutide a development advantage in this specific indication, while Eli Lilly’s broader program (obesity, diabetes, MASH) spreads resources across multiple regulatory filings.

Conclusion

Retatrutide and survodutide share the distinction of incorporating glucagon receptor agonism into incretin-based therapy, but they approach the design from different angles. Retatrutide’s triple agonism provides the broadest receptor coverage and the most potent weight loss data — now confirmed at the Phase 3 level by TRIUMPH-4 — while survodutide’s dual GLP-1/glucagon design is more streamlined and has been strategically positioned for MASLD/MASH indications.

The emerging clinical data from their respective Phase 3 programs will clarify the relative merits of each approach. In particular, survodutide’s Phase 3 obesity and MASH data, when available, will provide a more definitive comparison. Both represent important advances in metabolic pharmacology that could benefit distinct patient populations.

Frequently Asked Questions

Which drug is more effective for weight loss, retatrutide or survodutide?

Based on available data, retatrutide produces greater weight loss. TRIUMPH-4 Phase 3 data showed -28.7% weight loss with retatrutide 12 mg at 68 weeks, while survodutide achieved approximately 18-19% in Phase 2 at 46 weeks. The difference is likely driven by retatrutide’s additional GIP receptor agonism. However, survodutide’s Phase 3 data have not yet been reported, and the final comparison may narrow.

Why does retatrutide target three receptors while survodutide only targets two?

The molecules were designed by different companies with different pharmacological strategies. Eli Lilly built retatrutide by adding a glucagon receptor to their existing GIP/GLP-1 dual agonist expertise (from tirzepatide). Boehringer Ingelheim designed survodutide by combining GLP-1 with glucagon receptor agonism without GIP. The question of whether two or three receptors is optimal remains an active area of research.

Which drug is better for fatty liver disease (MASLD/MASH)?

Both drugs show potent liver fat reduction due to their shared glucagon receptor component. Boehringer Ingelheim has made MASH a primary strategic focus for survodutide, conducting dedicated trials with liver biopsy endpoints. Eli Lilly is evaluating retatrutide for MASH through the SYNERGY trial. Phase 2 data suggest retatrutide may achieve greater liver fat reduction (~82% relative), but head-to-head and Phase 3 MASH data are needed for a definitive answer.

Are these drugs available to patients now?

No. Both retatrutide and survodutide are investigational and available only through enrollment in authorized clinical trials as of March 2026. Neither has been approved by the FDA, EMA, or any other regulatory authority. Neither can be prescribed or purchased at pharmacies.

What is the dysesthesia side effect, and does survodutide cause it too?

Dysesthesia refers to abnormal sensory sensations (numbness, tingling, burning). It was reported in 20.9% of retatrutide 12 mg participants in TRIUMPH-4, a Phase 3 trial. Survodutide has not reported a comparable signal, but its Phase 2 trials enrolled fewer participants, which may limit detection of less common effects. Whether this is related to the glucagon receptor (shared by both drugs) or the triple receptor combination is not yet clear.

Which company has a stronger development program in this space?

Both companies have robust programs. Eli Lilly benefits from its established tirzepatide franchise (Mounjaro/Zepbound) and extensive experience with incretin-based therapies. Boehringer Ingelheim has partnered strategically on survodutide and focused specifically on the MASH/liver disease space. Eli Lilly’s TRIUMPH program is larger overall (7+ trials), while Boehringer Ingelheim’s concentrated MASH focus may give survodutide a faster path to approval in that specific indication.

Do both drugs increase energy expenditure?

Yes, both drugs are expected to increase energy expenditure through their shared glucagon receptor component. Glucagon receptor activation stimulates hepatic thermogenesis and fatty acid oxidation, causing the liver to burn more calories. This mechanism distinguishes both retatrutide and survodutide from GLP-1-only agonists (like semaglutide) and GIP/GLP-1 dual agonists (like tirzepatide), which primarily reduce caloric intake without substantially increasing energy expenditure. Retatrutide’s additional GIP receptor may contribute further to metabolic effects, but the glucagon component is the primary driver of increased energy expenditure in both drugs.

When will we know which drug is better?

A definitive answer requires Phase 3 data from both programs and ideally a head-to-head clinical trial, which has not been conducted and may never be (since the drugs are made by competing companies). Retatrutide has Phase 3 data from TRIUMPH-4 (December 2025), while survodutide’s Phase 3 results are pending as of March 2026. Once both programs report Phase 3 data, cross-trial comparisons will become more informative, though still subject to methodological limitations.